Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

By /


Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top